Clinical Trials for Oncology

Diffuse Large B-Cell Lymphoma (DLBCL) is the most common subtype of non-Hodgkin lymphoma, accounting for 85% of cases. It results from genetic mutations that transform healthy B-cells into fast-growing cancer cells, which can spread rapidly to lymph nodes and other organs. About 60-70% of patients achieve long-term remission, with prognosis influenced by factors like age, overall health, and disease stage. Early detection and personalized treatment are crucial for better outcomes. Some cases resist standard treatments, prompting researchers to explore alternative therapies.

At NHO Revive, we are committed to developing new treatments for DLBCL through innovative clinical trials. Our clinical trial for cancer focuses on creating novel drugs that target the underlying mechanisms of the disease, aiming to improve patient outcomes and offer new hope in the fight against this aggressive cancer.

Myelofibrosis is a rare bone marrow cancer that disrupts normal blood cell production, affecting 1 to 9 in every 100,000 people. This condition causes significant scarring in the bone marrow, leading to severe anemia, which results in weakness and fatigue. The scarring also reduces platelet numbers, increasing bleeding risk, and often causes an enlarged spleen. Myelofibrosis can occur independently (primary) or develop from another bone marrow disorder (secondary).

NHO Revive’s myelofibrosis clinical trial for cancer aims to investigate the safety and efficacy of an investigational drug with the potential to effectively target this cancer. Our commitment is to bring innovative treatments to patients, enhancing their well-being and quality of life.

B-cell lymphoma is an aggressive cancer that targets the white blood cells responsible for fighting infections. Classic lymphoma typically grows slowly and gradually, classified as a form of non-Hodgkin lymphoma. Our follicular lymphoma clinical trials for cancer aim to evaluate the safety and efficacy of an investigational drug in individuals with relapsed or refractory diffuse large B-cell lymphoma.

Participants must have follicular lymphoma and have received at least one prior systemic therapy. These clinical trials for oncology involve a higher treatment burden than standard therapies. To monitor the investigational drug’s effects, participants will undergo regular medical assessments at an approved institution, ensuring comprehensive evaluation and safety monitoring throughout the study.

Chronic myelogenous leukemia (CML) is a cancer originating in the blood-forming cells of the bone marrow, leading to uncontrolled growth of abnormal white blood cells due to DNA changes. This CML research study spans three phases to evaluate the efficacy of the investigational drug. Patients will be screened for specific mutations and excluded if such mutations are detected.

These clinical trials aim to discover new, effective treatments for patients with bone marrow cancer. Our clinical trials for cancer involve a comprehensive assessment of the investigational drug to ensure its efficacy and safety in treating CML. By participating, patients contribute to advancing potential treatments and improving outcomes for those affected by this type of cancer.